Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients

Summary

This study is testing different dosing schedules of EMB-01 in patients with advanced colorectal cancer whose disease has recurrent or progressed on previous treatments. Patients will be randomly assigned to one of two dosing schedules: EMB-01 once weekly, or once weekly for 6 weeks then every two weeks.

Timeline

Start

2025-12-18

Primary completion

2027-12-30

Completion

2028-06-30

Drugs

Indications